Thu, 03 Nov 2016 07:52:49 GMT
Baxter starts phase 3 trial of new therapy for acute kidney injury
- Pharmaceutical Business ReviewBaxter
acute therapies medical director Farah Ali said: “One potential obstacle in delivering effective CRRT occurs when blood flow through the circuit is slowed or completely stopped by blood clots. “Extending the life of the extracorporeal circuit ...
Thu, 03 Nov 2016 06:20:04 GMT
Wed, 02 Nov 2016 21:16:30 GMT
Wed, 02 Nov 2016 20:30:51 GMT
Wed, 02 Nov 2016 19:44:23 GMT
Wed, 02 Nov 2016 18:21:49 GMT
Baxter International Inc. (NYSE:BAX) Analyst Estimates And Rating
- The Independent RepublicBaxter International
Inc. (NYSE:BAX) stock is presently standing at about $46.89 and lots of equity research firms seem to have a target price set on the stock. The median one-year price target of 12 analysts covering the company is $53.00, which ...
Wed, 02 Nov 2016 17:47:30 GMT
Wed, 02 Nov 2016 17:08:05 GMT
Wed, 02 Nov 2016 16:15:12 GMT
Wed, 02 Nov 2016 15:51:34 GMT
Baxter International Inc. (NYSE:BAX): Sell-Side Focus
- Transcript Daily
For the quarter ending 2016-12-31, analysts have $0.78 as the consensus EPS estimate for Baxter International
Inc. (NYSE:BAX). But on or around 2017-02-07, the company is expected to post its next earnings numbers. $0.56 is the last posted EPS, which ...